Oruka Therapeutics, Inc. ORKA
109.50 USD +4.94 (+4.72%)
At closeNov 10, 2026, 4:41 PM EST
109.50 0.00 0.00%
After hours · Nov 10, 4:41 PM ET
102.78 Day range 113.24
25.23 52-week range 115.52
- YTD
- +261.27%
- 1 year
- +291.63%
- Market cap
- 7.25B
- EPS (ttm)
- -2.04
- Shares out
- 66.21M
- Forward P/E
- -37.19
- YTD return
- +261.27%
- 1-year return
- +291.63%
- Volume
- 2.61M
- Avg volume
- 946.88K
- Open
- 103.84
- Previous close
- 104.56
- Day's range
- 102.78 – 113.24
- 52-week range
- 25.23 – 115.52
- Analysts
- Strong Buy
- Price target
- 156.17 (+42.6%)
- Earnings date
- Mar 11, 2027
5D +9.39 (+9.36%)
Key statistics
- Enterprise value
- 6.18B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -95.07M
- Total cash
- 920.28M
- Total debt
- 2.93M
- Return on equity
- -18.12%
- Short % of float
- 13.44%
- 50-day average
- 88.48
- 200-day average
- 71.21
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 156.17 +42.6% upside
Now 109.50
- Target (low)
- 117.00
- Target (mean)
- 156.17
- Target (high)
- 200.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy2
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -0.68458.
Financials — quick view
ORKA Revenue — quarterly 0
ORKA Net income — quarterly -49.97K
ORKA EPS — quarterly -0.63
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Dec 30, 2026 | -0.67 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.59959 | -0.63 | -0.03 | -5.07% |
| Aug 10, 2026 | Jun 30, 2026 | -0.51249 | -0.55 | -0.04 | -7.32% |
| May 13, 2026 | Mar 31, 2026 | -0.54692 | -0.48 | +0.07 | +12.24% |
| Mar 12, 2026 | Dec 31, 2025 | -0.61 | -0.45 | +0.16 | +26.23% |
| Nov 12, 2025 | Sep 30, 2025 | -0.56 | -0.55 | +0.01 | +1.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | BTIG | reit | Buy | Buy |
| Oct 27, 2026 | Guggenheim | reit | Buy | Buy |
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Sep 24, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- orukatx.com
News
Oruka Therapeutics Q3 EPS $(0.63) Misses $(0.60) Estimate 
Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Oruka Therapeutics, Inc. $ORKA Stock: Candriam S.C.A. Lowers Holdings 
Oruka Therapeutics to Participate in Multiple Upcoming Conferences 
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target 
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target 
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target 
Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study 
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript 
Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial
Your note
Sign in to keep a note on ORKA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGARWAL ARJUN | Officer | Sale | Oct 11, 2026 | 14,219 |
| DAMBKOWSKI CARL | Director | Sale | Jun 11, 2026 | 38,743 |
| EDWARDS LARRY TODD | Officer | Stock Award(Grant) | Aug 23, 2026 | 100,000 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 30, 2026 | 0 |
| GONCALVES JOANA | Officer | Sale | Sep 14, 2026 | 31,771 |
| KLEIN LAWRENCE OTTO | Chief Executive Officer | Sale | Nov 1, 2026 | 923,128 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.68% | 9,057,645 | 991.81M | Jun 29, 2026 |
| Blackrock Inc. | 7.54% | 4,990,181 | 546.42M | Jun 29, 2026 |
| Venrock Adviser, LLC | 6.27% | 4,148,428 | 454.25M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 5.60% | 3,705,262 | 405.73M | Jun 29, 2026 |
| Capital World Investors | 5.14% | 3,401,639 | 372.48M | Jun 29, 2026 |
| RTW Investments LP | 4.74% | 3,139,030 | 343.72M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.60% | 1,724,692 | 188.85M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.44% | 1,614,957 | 176.84M | Sep 29, 2026 |
| SmallCap World Fund Inc | 2.31% | 1,527,592 | 167.27M | Sep 29, 2026 |
| New Economy Fund | 2.00% | 1,323,308 | 144.90M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.97% | 1,304,825 | 142.88M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.95% | 1,294,135 | 141.71M | Sep 29, 2026 |